Akthelia Pharmaceuticals is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Akthelia Pharmaceuticals. A preclinical drug development startup, Akthelia has developed a new method for fighting infections using new chemical entities which act by stimulating the production of naturally occurring antimicrobial peptides in the body. The antibacterial peptides kill bacteria, including antibiotic-resistant strains. Akthelia focuses on resistant Klebsiella lung infections.
Company size
1-10 employees
Headquarters
Reykjavík, Capital Region